@book{BockGauchGiernatetal.2013,
  author    = {Bock, Stefanie and Gauch, Fabian and Giernat, Yannik and Hillebrand, Frank and Kozlova, Darja and Linck, Lisa and Moschall, Rebecca and Sauer, Markus and Schenk, Christian and Ulrich, Kristina and Bodem, Jochen},
  title     = {HIV-1 : Lehrbuch von Studenten f{\"u}r Studenten},
  organization    = {Bachelor- und Masterkurs Virologie 2013},
  isbn      = {978-3-923959-90-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-78980},
  publisher      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Dies ist ein Lehrbuch {\"u}ber die HIV-1 Replikation, Pathogenese und Therapie. Es richtet sich an Studenten der Biologie und der Medizin, die etwas mehr {\"u}ber HIV erfahren wollen und stellt neben virologischen Themen auch die zellul{\"a}ren Grundlagen dar. Es umfasst den Viruseintritt, die reverse Transkription, Genom-Integration, Transkriptionsregualtion, die Kotrolle des Spleißens, der Polyadenylierung und des RNA-Exportes. Die Darstellung wird abgerundet mit Kapiteln zum intrazellul{\"a}rem Transport, zu Nef und zum Virusassembly. In zwei weiteren Kapitel wird die HIV-1 Pathogenese und die Therapie besprochen. Zur Lernkontrolle sind den Kapiteln Fragen und auch Klausurfragen angef{\"u}gt.},
  subject      = {HIV},
  language  = {de}
}
@article{LapaKircherHaenscheidetal.2018,
  author    = {Lapa, Constantin and Kircher, Malte and H{\"a}nscheid, Heribert and Schirbel, Andreas and Grigoleit, G{\"o}tz Ulrich and Klinker, Erdwine and B{\"o}ck, Markus and Samnick, Samuel and Pelzer, Theo and Buck, Andreas K},
  title     = {Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients},
  series = {Theranostics},
  volume    = {8},
  journal   = {Theranostics},
  number    = {3},
  doi       = {10.7150/thno.22161},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-158983},
  pages     = {644-649},
  year      = {2018},
  abstract  = {Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10\% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors. Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT. Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient \#1) and stable disease regarding morphology as well as disease activity (patient \#2), respectively. Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.},
  language  = {en}
}